INOTEK PHARMACEUTICALS CORP's ticker is and the CUSIP is 45780VAB8. A total of 9 filers reported holding INOTEK PHARMACEUTICALS CORP in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,880,000 | -14.3% | 2,000,000 | 0.0% | 0.43% | +1.2% |
| Q4 2019 | $2,194,000 | +9.7% | 2,000,000 | 0.0% | 0.43% | +3.1% |
| Q3 2019 | $2,000,000 | 0.0% | 2,000,000 | 0.0% | 0.42% | -2.6% |
| Q2 2019 | $2,000,000 | 0.0% | 2,000,000 | 0.0% | 0.43% | +9.0% |
| Q1 2019 | $2,000,000 | +4.2% | 2,000,000 | 0.0% | 0.39% | -4.4% |
| Q4 2018 | $1,920,000 | -13.5% | 2,000,000 | 0.0% | 0.41% | -4.9% |
| Q3 2018 | $2,220,000 | +8.8% | 2,000,000 | 0.0% | 0.43% | +5.9% |
| Q2 2018 | $2,040,000 | +16.6% | 2,000,000 | 0.0% | 0.41% | +10.9% |
| Q1 2018 | $1,750,000 | +9.4% | 2,000,000 | 0.0% | 0.37% | +5.5% |
| Q4 2017 | $1,600,000 | +1.3% | 2,000,000 | 0.0% | 0.35% | -1.7% |
| Q3 2017 | $1,580,000 | +31.7% | 2,000,000 | 0.0% | 0.35% | +28.8% |
| Q2 2017 | $1,200,000 | +0.8% | 2,000,000 | 0.0% | 0.27% | -3.9% |
| Q1 2017 | $1,190,000 | -42.8% | 2,000,000 | 0.0% | 0.28% | -47.5% |
| Q4 2016 | $2,080,000 | – | 2,000,000 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TFG Asset Management GP Ltd | 9,700,000 | $10,181,000 | 2.02% |
| Telemetry Investments, L.L.C. | 1,000,000 | $1,040,000 | 0.59% |
| DAFNA Capital Management LLC | 600,000 | $618,000 | 0.54% |
| Bruce & Co., Inc. | 2,000,000 | $2,080,000 | 0.54% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 5,700,000 | $5,928,000 | 0.29% |
| Orbimed Advisors | 7,000,000 | $7,354,000 | 0.09% |
| Baker Brothers Advisors | 5,000,000 | $5,167,000 | 0.05% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 2,000,000 | $2,044,000,000 | 0.04% |
| Citadel Advisors | 15,000,000 | $15,394,000 | 0.02% |
| WOLVERINE ASSET MANAGEMENT LLC | 1,000,000 | $1,033,000 | 0.01% |